AmMax Bio

AmMax Bio is a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, with a focus on colorectal cancer minimal residual disease (CRC MRD).

Having previously collaborated with AmMax on an investor deck, we were excited to help refine the narrative for the next stage of their fundraising journey. Working closely with the team, we shaped the evolving story, ensuring the pitch deck, website, and mechanism-of-action illustrations effectively highlight AmMax’s differentiated CSF1R-targeting platform.

The result was a cohesive suite of materials that effectively communicates AmMax Bio’s vision and scientific strategy to investors and industry partners.

Title slide for the AmMax Bio investor presentation. Features an abstract illustration representing antibodies and interactions, with the company logo 'AmMAX' prominently displayed.
This slide from an AmMax Bio investor deck explains minimal residual disease (MRD) in colorectal cancer (CRC) and its potential to lead to liver metastasis. Illustrations of the colon, a magnifying glass highlighting MRD, and the liver are shown. The slide also mentions circulating tumor DNA (ctDNA) as a biomarker.
An illustrative slide from AmMax Bio's investor deck detailing how AMB-066 targets and depletes pro-tumorigenic macrophages, potentially blocking MRD progression to metastasis in colorectal cancer. The design includes visual representations of immune cells and the impact on the colon and liver.
This investor deck slide from AmMax Bio highlights the market opportunity for treating CRC MRD in the US and EU. It uses visual representations of people and currency symbols to convey the number of surgical cases and the potential market size.
This slide from an AmMax Bio investor deck focuses on Acute Myeloid Leukemia (AML), outlining the disease, current treatments, and significant unmet needs for more efficacious and less toxic therapies. An illustration of leukemic blasts is included.